Savara (SVRA) announced Yasmine Wasfi, M.D., Ph.D., FCCP has been promoted to CMO, effective immediately. She succeeds Ray Pratt, M.D., FACP who will transition from his current role to Senior Medical Advisor. Dr. Wasfi will report directly to the Company’s Chair and Chief Executive Officer and will serve as a member of the executive leadership team. Previously, Dr. Wasfi was Executive Vice President, Head of Clinical Development and Clinical Operations at Savara.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara initiated with an Outperform at LifeSci Capital
- Savara’s MOLBREEVI: A Promising Solution for Autoimmune Pulmonary Alveolar Proteinosis with Blockbuster Potential
- Savara present results from Phase 3 IMPALA-2 Molgramostim study
- Savara management to meet virtually with Piper Sandler
- Savara Inc. Faces Legal Battle Over MOLBREEVI Controversy